STAT+: Oncologists turn to blood test for circulating tumor DNA, but questions remain on how to use the data
The hope for many cancer patients who go through surgery is that they’ll be cured…
Category: ASCO
STAT+: Oncologists turn to blood test for circulating tumor DNA, but questions remain on how to use the data
The hope for many cancer patients who go through surgery is that they’ll be cured…
STAT+: ASCO Daily Recap: A CAR-T advance, money talk, and tossing the cancer treatment ‘sandwich’
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American…
STAT+: At ASCO, AstraZeneca says its CAR-T therapy shrank solid liver tumors in early trial
CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with…
STAT+: ASCO Daily Recap: AstraZeneca’s hat trick, a GSK turnaround, and palliative care as telehealth
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American…
Palliative care for cancer patients is found to be as effective given virtually as in person
CHICAGO — Comfort can be delivered to patients with advanced cancer virtually just as well…
STAT+: AstraZeneca’s Tagrisso greatly slows cancer for some people with stage 3 lung cancer
In patients with stage 3 lung cancer where a particular genetic mutation is present in…
STAT+: With new results at ASCO, Enhertu once again rewrites rules of breast cancer treatment
CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a…
STAT+: At ASCO, pharma leaders explain how ‘smart bomb’ drugs became useful against more cancers
CHICAGO — The ways clinicians can treat cancers effectively are expanding, partly because technologies today…
STAT+: ASCO 2024: FDA oncology head wants clinical trials to range beyond China alone
CHICAGO — The Food and Drug Administration’s top oncologist reiterated that the agency doesn’t want drugmakers…
STAT+: With expectations rising, Corbus reveals new data on its ADC bladder cancer treatment
CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor…
STAT+: Watch: An interview with the FDA’s top cancer regulator
On Friday, Richard Pazdur, the director of the FDA Oncology Center of Excellence, sat down…
STAT+: A dose of transparency by Cel-Sci does nothing to burnish its failed cancer immunotherapy
CHICAGO — I met Cel-Sci CEO Geert Kersten for the first time on Monday at…
STAT+: Adicet ‘gamma-delta’ T cell therapy shows complete remissions in early study of lymphoma patients
CHICAGO — Adicet Bio reported Monday that a unique, off-the-shelf therapy made from a special…
With the right molecular signal, a cancer drug works in every patient
Sascha Roth was in her late 30s and feeling great. Then she noticed some bleeding…
STAT+: Roche’s Tigit troubles escalate, sparking more debate about the closely tracked cancer immunotherapy target
CHICAGO — Roche had previously announced the failure of its closely tracked anti-TIGIT immunotherapy in…
STAT+: Promising results reported for new generation of CAR-T immunotherapy for myeloma
CHICAGO — Three companies presented Phase 1 clinical trial results on new CAR-T therapies for…
STAT+: Enhertu, a smart bomb drug, dramatically extends survival in breast cancer patients
CHICAGO — The cancer drug Enhertu cut the rate of death in a group of…
STAT+: In study, Gilead’s Trodelvy shows modest benefit in breast cancer patients
CHICAGO — The cancer drug Trodelvy reduced the risk of tumors progressing by 34% compared…
STAT+: The FDA’s Pazdur on accelerated approval, single-arm studies, and his own future
CHICAGO — When cancer drugs granted accelerated approval in the U.S. later turn out not…
Weight loss from bariatric surgery is associated with a reduced risk of cancer in study
Undergoing bariatric surgery in order to lose weight may substantially reduce some patients’ risk of…
STAT+: With new data on its KRAS-blocking lung cancer drug, Mirati expects to take on a rival Amgen treatment
As Mirati Therapeutics waits for the Food and Drug Administration to complete a review of…
Virtual Event: The ASCO Recap, Live!
After the biggest meeting in cancer research, sit down with cancer’s biggest decision-maker: the director…
STAT+: Radioactive drug helps men with advanced prostate cancer, but survival benefit is debated
A Novartis drug that delivers a lethal dose of radiation directly to prostate cancer cells…
STAT+: Fate Therapeutics’ natural killer cells induce responses in blood cancer patients, but for how long?
Fate Therapeutics said Friday that an experimental, off-the-shelf immunotherapy made from so-called natural killer cells…
STAT+: For first time, immunotherapy after surgery shows benefit for patients with early kidney cancer
Merck said Thursday that giving its drug Keytruda immediately after surgery significantly reduced the risk…
STAT+: STAT+ Conversations: A look ahead to ASCO 2021
Editor’s note: A livestream of this conversation will be embedded below at 1 p.m. ET….
STAT+: Allogene’s blood cancer data show durability of off-the-shelf CAR-T cells
There’s little disputing that an off-the-shelf CAR-T cell therapy for cancer would provide flexibility and…
STAT+: With new data, J&J’s CAR-T drug benefits myeloma patients with less advanced disease
When doctors prescribe a personalized cell therapy today, the patient they’re trying to help has…
STAT+: In a step forward for immunotherapy, new Bristol Myers drug slows melanoma in study
An experimental immunotherapy developed by Bristol Myers Squibb prevented metastatic melanoma from worsening when added…
STAT+: Merus drug shows potential as treatment for rare type of pancreatic cancer
A drug from the Dutch biotech Merus designed to disrupt a rare genetic alteration is…
STAT Plus: ASCO 2020 takeaways: AstraZeneca does a star turn, KRAS fizzles, and cell therapy shows progress
The annual meeting American Society of Clinical Oncology (ASCO) concluded on Sunday. The closely-followed cancer…
Opinion: Early diagnosis, not cancer drug breakthroughs, is the best way to fix the global scourge of breast cancer
Covid-19 news could be nudged out of the spotlight this weekend as the American Society…
STAT Plus: Additional blood cancer responses seen with Allogene’s off-the-shelf CAR-T cells, updated study shows
Allogene on Friday released updated results from the first study of its off-the-shelf CAR-T cell…
KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Demonstrated Clinically Meaningful Tumor Response Rates in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma
Dateline City: KENILWORTH, N.J. & WOODCLIFF LAKE, N.J. Analyses from KEYTRUDA Plus LENVIMA Trials to…
Merck’s KEYTRUDA® (pembrolizumab) Superior to Standard of Care Chemotherapy in Patients with MSI-H Colorectal Cancer
Dateline City: KENILWORTH, N.J. KEYTRUDA Monotherapy Significantly Reduced Risk of Disease Progression or Death by…
STAT Plus: AstraZeneca study results could change treatment for certain early-stage lung cancer patients
In April, AstraZeneca halted a clinical trial of its genetically targeted lung cancer drug Tagrisso…
Merck’s KEYTRUDA® (pembrolizumab) Superior to Brentuximab Vedotin (BV), a Standard of Care, in Patients With Classical Hodgkin Lymphoma (cHL) in Head-to-Head Phase 3 Trial
Dateline City: KENILWORTH, N.J. KEYNOTE-204 is the First Positive Phase 3 Trial of an Anti-PD-1…
STAT Plus: Roche’s novel checkpoint inhibitor delivers mixed results in new lung cancer study
Roche on Wednesday said a two-drug combination that includes a novel but still experimental checkpoint-blocking…
STAT Plus: Some blood cancer patients see remission with Allogene’s off-the-shelf CAR-T cells, early data show
Allogene on Wednesday released the first data on tumor responses to its off-the-shelf CAR-T cell…